NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 124 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,519 | -48.6% | 28,522 | +24.4% | 0.00% | – |
| Q2 2023 | $59,397 | -31.5% | 22,933 | +8.0% | 0.00% | – |
| Q1 2023 | $86,651 | -11.2% | 21,238 | +9.2% | 0.00% | – |
| Q4 2022 | $97,615 | -87.9% | 19,445 | -68.6% | 0.00% | – |
| Q3 2022 | $809,000 | +16.7% | 61,903 | +14.7% | 0.00% | – |
| Q2 2022 | $693,000 | -17.7% | 53,980 | -2.3% | 0.00% | – |
| Q1 2022 | $842,000 | -8.5% | 55,238 | +6.4% | 0.00% | – |
| Q4 2021 | $920,000 | -11.0% | 51,925 | +5.5% | 0.00% | – |
| Q3 2021 | $1,034,000 | +249.3% | 49,195 | +228.2% | 0.00% | – |
| Q2 2021 | $296,000 | -70.7% | 14,991 | -56.9% | 0.00% | – |
| Q1 2021 | $1,011,000 | -56.8% | 34,766 | -55.0% | 0.00% | -100.0% |
| Q4 2020 | $2,338,000 | +234.0% | 77,178 | +75.3% | 0.00% | – |
| Q3 2020 | $700,000 | -6.3% | 44,017 | +16.3% | 0.00% | – |
| Q2 2020 | $747,000 | – | 37,832 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |